Home › Funds › GENEVA CAPITAL MANAGEMENT LLC › TECH
GENEVA CAPITAL MANAGEMENT LLC position in TECH
BIO-TECHNE CORP · Health Care
GENEVA CAPITAL MANAGEMENT LLC reported holding 884,168 shares of TECH (BIO-TECHNE CORP) in its Q3 2026 13F filing — a position valued at US$64.1M, representing 1.79% of its reported portfolio and ranking #19 among its reported holdings. GENEVA CAPITAL MANAGEMENT LLC has disclosed TECH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How GENEVA CAPITAL MANAGEMENT LLC's TECH position evolved
GENEVA CAPITAL MANAGEMENT LLC first disclosed a stake in TECH in Q3 2023 at 1,069,934 shares (US$72.8M). The position peaked in Q3 2024 at 1,104,310 shares, worth US$88.3M. Across 13 filings, GENEVA CAPITAL MANAGEMENT LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 884,168 shares valued at US$64.1M — a reduction of -127,909 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.07M | $72.83M | New |
| Q4 2023 | 1.08M | $83.28M | Add |
| Q1 2024 | 1.08M | $76.02M | Hold |
| Q2 2024 | 1.09M | $77.90M | Add |
| Q3 2024 | 1.10M | $88.27M | Add |
| Q4 2024 | 1.09M | $78.51M | Reduce |
| Q1 2025 | 1.10M | $64.42M | Add |
| Q2 2025 | 1.19M | $60.97M | Add |
| Q3 2025 | 1.19M | $65.92M | Hold |
| Q4 2025 | 1.09M | $64.13M | Reduce |
| Q1 2026 | 1.24M | $64.96M | Add |
| Q2 2026 | 1.01M | $71.50M | Reduce |
| Q3 2026 | 884.17K | $64.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TECH and 13F data
TECH (BIO-TECHNE CORP) is a Health Care company. 27 other funds we track also report a position in TECH — the largest reported positions include HBK INVESTMENTS L P (US$482.2M), Ruane Cunniff & Goldfarb (Sequoia) (US$236.6M), SNYDER CAPITAL MANAGEMENT L P (US$223.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TECH
- HBK INVESTMENTS L P 6.83M sh · $482.19M · Q2 2026
- Ruane Cunniff & Goldfarb (Sequoia) 3.35M sh · $236.60M · Q2 2026
- SNYDER CAPITAL MANAGEMENT L P 3.16M sh · $223.52M · Q2 2026
- MAIRS & POWER INC 2.70M sh · $190.80M · Q2 2026
- Qube Research & Technologies Ltd 2.38M sh · $172.44M · Q3 2026
- WHITEBOX ADVISORS LLC 2.10M sh · $148.37M · Q2 2026
- RGM Capital, LLC 2.15M sh · $126.56M · Q4 2025
More on GENEVA CAPITAL MANAGEMENT LLC
FAQ
How long has GENEVA CAPITAL MANAGEMENT LLC held TECH?
GENEVA CAPITAL MANAGEMENT LLC has disclosed TECH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is GENEVA CAPITAL MANAGEMENT LLC's current position in TECH?
As of Q3 2026, GENEVA CAPITAL MANAGEMENT LLC holds 884.17K shares of TECH (BIO-TECHNE CORP), valued at $64.08M, representing 1.79% of its reported portfolio and ranking #19.
Has GENEVA CAPITAL MANAGEMENT LLC been buying or selling TECH?
In the latest 13F filing (Q3 2026), GENEVA CAPITAL MANAGEMENT LLC reduced its position in TECH. The position peaked in Q3 2024 at 1.10M shares.
Which other funds hold TECH?
Other major institutional holders of TECH include HBK INVESTMENTS L P, Ruane Cunniff & Goldfarb (Sequoia), SNYDER CAPITAL MANAGEMENT L P, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.